Management of trastuzumab cardiotoxicity (breast and gastric cancer)
Alessandro Inno
(Thanks to Dr. Alessandro Inno for sharing this presentation through cardioncology.org)
Download presentation in PDF format
PRESENTATION TOPICS
(presentation content in English language)
-
HER Receptors Family and Mechanisms of Action of Trastuzumab
-
Trastuzumab in Breast and Gastric Cancer
-
Trastuzumab Cardiotoxicity in Breast and Gastric Cancer
-
Pathogenesis of Trastuzumab Cardiotoxicity
-
Timing of Trastuzumab Cardiotoxicity: Data from the HERA trial
-
Cardiac Safety of Long-Term Trastuzumab – The ROP study
-
Reversibility of Trastuzumab Cardiotoxicity: Data from the HERA trial
-
Cardiotoxicity is the first cause of Trastuzumab discontinuation in the Breast Cancer adjuvant setting
-
Management of Trastuzumab Cardiotoxicity: Clinical Considerations
-
-
Primary prevention (Risk Factors, Cardioprotective Agents, De-escalating Treatment)
-
-
Risk Factors Related To Patient: CV Risk Factors
-
Risk Factors Related To Treatment: Previous Anthracyclines
-
ACEi / BBs / ARBs – MRI Studies: Results
-
Candesartan to prevent Trastuzumab-related Cardiotoxicity
-
Lisinopril or Carvedilol to prevent Trastuzumab-related Cardiotoxicity
-
Duration of Adjuvant Trastuzumab: 1-year vs less (9/26 wks)
-
-
-
Secondary prevention (Early diagnosis and Treatment)
-
-
Is There a Role for Biomarkers?
-
ECHO as a Monitoring Tool
-
Is There a Role for GLS?
-
Algorithm for the Management of Trastuzumab Cardiotoxicity: Italian Multi-Society Recommandations
-
Treatment of Trastuzumab Cardiotoxicity
-
-
-
Tertiary prevention (Trastuzumab in pts with Cardiac Events or Reduced LVEF at Baseline)
-
-
HER2-targeted Therapies in pts with Compromised Cardiac Function – The SAFE-HEaRt study
-
Continuing Trastuzumab Despite Mild Cardiotoxicity – The SCHOLAR study
-
-
-
-
-
Take-Home Messages
Download presentation in PDF format